Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04679740 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Resorbable Magnesium Scaffolds Registry

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 1, 2026 to May 2030 Study sites: 2 to 13 · Interventions: Magmaris (Device) to Freesolve (Device), Magmaris (Device)v3 Show 2 more changesShow less
    • Study sites: 2 to 13
    • Interventions: Magmaris (Device) to Freesolve (Device), Magmaris (Device)
  2. Primary completion date: Dec 1, 2022 to Dec 1, 2026 Completion date: Dec 1, 2023 to Dec 1, 2026 · Secondary endpoints shortened, about 15 wordsv2 Show 2 more changesShow less
    • Completion date: Dec 1, 2023 to Dec 1, 2026
    • Secondary endpoints shortened, about 15 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The registry follows the ESC/EACTS guideline and further investigates the clinical performance and short-term safety of RMS (Resorbable Magnesium Scaffolds) in a real world setting within the scope of its intended use without further (medical related) exclusion criteria according to their respective instructions for use (IFU).
Trial Details
NCT Number NCT04679740
Lead Sponsor Biotronik AG
Conditions Coronary Artery Disease
Enrollment 1,106 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov